IRIS
GIANNINI, EDOARDO GIOVANNI BATTISTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 38.545
AS - Asia 4.398
NA - Nord America 2.926
SA - Sud America 376
AF - Africa 77
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 5
Totale 46.335
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 37.692
US - Stati Uniti d'America 2.731
SG - Singapore 1.853
CN - Cina 1.135
VN - Vietnam 719
FR - Francia 386
BR - Brasile 234
BD - Bangladesh 226
HK - Hong Kong 152
FI - Finlandia 126
DE - Germania 102
CA - Canada 80
AR - Argentina 70
MX - Messico 69
GB - Regno Unito 64
JP - Giappone 56
IN - India 38
ID - Indonesia 33
CH - Svizzera 30
IQ - Iraq 26
NL - Olanda 24
EC - Ecuador 21
RU - Federazione Russa 19
ES - Italia 15
UZ - Uzbekistan 15
IE - Irlanda 14
JM - Giamaica 14
ZA - Sudafrica 14
CL - Cile 13
MA - Marocco 13
SA - Arabia Saudita 13
UA - Ucraina 13
PH - Filippine 12
PK - Pakistan 12
AE - Emirati Arabi Uniti 11
CO - Colombia 11
JO - Giordania 11
PL - Polonia 11
AZ - Azerbaigian 10
NP - Nepal 10
VE - Venezuela 10
KR - Corea 9
TR - Turchia 9
CR - Costa Rica 8
DZ - Algeria 8
KE - Kenya 8
TW - Taiwan 8
AU - Australia 7
SE - Svezia 7
ET - Etiopia 6
PY - Paraguay 6
TH - Thailandia 6
TN - Tunisia 6
UY - Uruguay 6
AL - Albania 5
AT - Austria 5
CZ - Repubblica Ceca 5
KZ - Kazakistan 5
NI - Nicaragua 5
HN - Honduras 4
LB - Libano 4
MY - Malesia 4
OM - Oman 4
PE - Perù 4
PT - Portogallo 4
RS - Serbia 4
XK - ???statistics.table.value.countryCode.XK??? 4
BE - Belgio 3
CY - Cipro 3
DO - Repubblica Dominicana 3
EG - Egitto 3
IL - Israele 3
BG - Bulgaria 2
BZ - Belize 2
CD - Congo 2
CG - Congo 2
CI - Costa d'Avorio 2
GA - Gabon 2
GT - Guatemala 2
HU - Ungheria 2
LT - Lituania 2
LV - Lettonia 2
NG - Nigeria 2
PS - Palestinian Territory 2
SN - Senegal 2
TT - Trinidad e Tobago 2
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BM - Bermuda 1
BO - Bolivia 1
BY - Bielorussia 1
CU - Cuba 1
CW - ???statistics.table.value.countryCode.CW??? 1
DJ - Gibuti 1
DK - Danimarca 1
GH - Ghana 1
GR - Grecia 1
IR - Iran 1
KG - Kirghizistan 1
KH - Cambogia 1
Totale 46.316
Salva come PNG Salva come JPEG
Città #
Genova 21.585
Genoa 9.971
Rapallo 3.046
Vado Ligure 2.542
Singapore 825
San Jose 768
Lauterbourg 358
Ashburn 306
Council Bluffs 240
New York 204
Ho Chi Minh City 200
Beijing 174
Hanoi 171
Hong Kong 145
Helsinki 102
Frankfurt am Main 81
Santa Clara 80
Bordighera 70
Boardman 64
Los Angeles 63
Milan 54
Tokyo 52
Mexico City 43
Rome 42
Orem 37
Chicago 33
Da Nang 28
Haiphong 27
Turin 27
São Paulo 26
Zurich 26
Lappeenranta 23
Dallas 22
Tianjin 22
Buffalo 21
St Louis 21
Montreal 20
Naples 19
Atlanta 17
Amsterdam 16
Phoenix 16
Toronto 16
Dublin 14
Cardiff 13
Charlotte 13
Des Moines 13
San Francisco 13
Shanghai 13
Tashkent 13
Bologna 12
Guangzhou 12
Hải Dương 12
Amman 11
Houston 11
Kingston 11
Warsaw 11
Baghdad 10
Brescia 10
Brooklyn 10
City of London 10
Denver 10
Dubai 10
Palermo 10
Poplar 10
Baku 9
Quảng Ngãi 9
Seattle 9
Biên Hòa 8
Columbus 8
London 8
Memphis 8
Miami 8
Nairobi 8
Tampa 8
Ancona 7
Dhaka 7
Guayaquil 7
Mumbai 7
Stockholm 7
Vinh 7
Bari 6
Bình Phước 6
Can Tho 6
Jeddah 6
Manchester 6
Montevideo 6
Piscataway 6
Quito 6
Rio de Janeiro 6
San José 6
Thái Bình 6
Vancouver 6
Brasília 5
Buenos Aires 5
Bắc Ninh 5
Catania 5
Chennai 5
Duque de Caxias 5
Hưng Yên 5
Johannesburg 5
Totale 42.092
Salva come PNG Salva come JPEG
Nome #
Hepatobiliary and Pancreatic: A rare cause of portal hypertension. 240
A new assay for hepatitis C virus (HCV) core antigen detection: an alternative to nucleic acid technologies in positive or indeterminate anti-HCV subjects? 220
5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: can we afford to wait for “best evidence”? 217
13C -Aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection. 211
Long-Term Follow-Up Study of Liver-Related Outcome After Bilio-Pancreatic Diversion in Patients with Initial, Significant Liver Damage 210
Positive PET in a patient with esophageal leiomyoma. 209
Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lémann Index 206
Leptin has no role in determining severity of steatosis and fibrosis in patients with chronic hepatitis C 204
Personalized treatment of patients with very early hepatocellular carcinoma 203
13C-galactose breath test and 13C-aminopyrine breath test for the study of liver function in chronic liver disease 202
Epidemiological and clinical features of hepatitis delta in HBsAg-positive patients by HIV status. 202
Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease. 193
Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. 192
A comparison between sodium alginate and magaldrate anhydrous in the treatment of patients with gastroesophageal reflux symptoms. 191
Application of the platelet count/spleen diameter ratio to rule out the presence of oesophageal varices in patients with cirrhosis: a validation study based on follow-up 190
A simple approach to noninvasively identifying significant fibrosis in chronic hepatitis C patients in clinical practice 189
Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice 189
High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease 187
A study of 4-and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication 187
Breath tests to assess alcoholic liver disease. 186
Acquired Hepatocerebral Degeneration in the Absence of Portosystemic Shunting 185
Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis 181
A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma 180
. Liver iron accumulation in chronic hepatittis C patients without HFE mutations: relationships with histological damage, viral load and genotype, and alpha glutathione S-transferase levels. 178
Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy 178
A Closer Look at Factors Associated With Bleeding in Cirrhotic Patients 178
Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth. 177
Cholestasis is the main determinant of abnormal CA 19-9 levels in patients with liver cirrhosis 177
Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. 174
Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients. 172
Hyaluronic acid and aspartate aminotransferase levels normalized by liver function can reflect sinusoidal impairment in chronic liver disease 171
IL28B rs12979860 C/T polymorphism in elderly chronic hepatitis C patients treated with pegylated-interferon and ribavirin. 170
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 170
Long term results of down-staging and liver transplantation for patients with hepatocellular carcinoma beyond the conventional criteria 170
Starry Liver: An Unexpected Diagnosis 167
A Nodule, is a Nodule, is a Nodule: May Alpha-fetoprotein Make the Difference? 167
Impact of evidence-based medicine on treatment of patients with unresectable hepatocellular carcinoma 166
Can the MEGX test and serum bile acids improve the prognostic ability of Child-Pugh's score in liver cirrhosis? 166
Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn’s disease. 166
Reduction in TIMP-2 serum levels predicts remission of inflammatory bowel diseases 166
A new approach to the use of alfa-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. 165
Adalimumab trough levels and response to biological treatment in patients with Inflammatory Bowel Disease: a useful cut-off In clinical practice. 164
Pattern of macrovascular invasion in hepatocellular carcinoma 163
Improvement in Waldenstrom’s macroglobulinemia after successful treatment of HCV with direct-acting antivirals 162
PRO: Cirrhotic patients with small esophageal varices should undergo primary prophylaxis 161
A summary of the 6th international conference on coagulation in liver disease: Discussion, debate, deliberations 160
A Liver Index and its Relationship to Indices of HCC Aggressiveness 160
Non-cirrhotic thrombocytopenic patients with hepatitis C virus: characteristics and outcome of antiviral therapy. 159
An independent validation of the mortality score for the short-term prognostic prediction in patients with chronic hepatitis C virus infection and advanced liver disease 159
Prevalence and prognostic significance of the presence of esophageal varices in patients with hepatocellular carcinoma 159
Bleeding after paracentesis in patients with decompensated cirrhosis and acute kidney injury: the perfect storm 159
12 weeks of interferon-based therapy is feasible in patients with hepatitis C-related cirrhosis and thrombocytopenia: A post hoc analysis of eltrombopag studies. 159
Successful antiviral therapy determines a significant decrease in squamous cell carcinoma antigen-associated (SCCA) variants' serum levels in anti-HCV positive cirrhotic patients. 158
Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens 158
Hepatocellular carcinoma in patients with cryptogenic cirrhosis 158
Effects of reduced glutathione and n-acetylcysteine on lidocaine metabolism in cimetidine treated rats 158
Harmonising proton pump inhibitors treatment in the specialist setting following the SIGE recommendations 158
Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study 158
Chronic hepatitis C in different populations: similar patterns of alanine aminotransferase alteration characterize similar clinical subgroups. 157
External Validation of the Platelet Count/Spleen Diameter Ratio for the Diagnosis of Esophageal Varices in Hepatitis C Virus-Related Cirrhosis 157
High ascitic fluid leptin levels in patients with decompensated liver cirrhosis and sterile ascites: Relationship with TNF-alpha levels 157
Utility of the MELD score for assessing 3-month survival in patients with liver cirrhosis: one more positive answer. 156
Curative therapies are superior to standard of care(transarterial chemoembolization)for intermediate stage hepatocellular carcinoma 156
Is there a role for multiple quantitative liver function tests? 155
Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease 155
Low Fibrinogen Levels Are Associated with Bleeding After Varices Ligation in Thrombocytopenic Cirrhotic Patients 155
The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin 155
Blessed are those who have not seen and yet have believed 154
Optimal management of constipation associated with irritable bowel syndrome. 154
Leptin in nonalcoholic steatohepatitis: is it one of the "hits"? 154
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon 154
Platelet dysfunction: status of thrombopoietin in thrombocytopenia associated with chronic liver failure 152
Transportability and reproducibility of the AST/ALT ratio in chronic hepatitis C patients. 152
MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study 152
Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma. 152
Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study. 152
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 152
13CO2 excretion in breath of normal subjects and cirrhotic patients after 13C-Aminopyrine oral load. Comparison with MEGX test in functional differentiation between chronic hepatitis and liver cirrhosis 151
Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: Implications for its clinical use. 150
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program 149
A randomized, 6-wk trial of a low FODMAP diet in patients with inflammatory bowel disease 149
Clinical and virological survey of patients with hepatitis B surface antigen in an Italian region: clinical considerations and disease burden 148
Prognosis of hepatocellular carcinoma in anti-HCV positive cirrhotic patients: a single-centre comparison amongst four different staging systems 147
Serum pro-collagen III peptide levels are related to lobular necrosis in untreated patients with chronic hepatitis C 147
Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome. 147
Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia 146
Plasma cholesterol and lipoprotein levels in relation to tumor aggressiveness and survival in HCC patients 146
Persistently normal aminotransferase in chronic hepatitis C virus infection: is it time to redefine parameters of "normality"? 145
Retrospective, observational, multicentre study on an Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combined therapy (PEG-IFN and ribavirin): NADIR study. 145
Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy. 145
Influence of 1-week helicobacter pylori eradication therapy with rabeprazole, clarithromycin, and metronidazole on 13C-aminopyrine breath test 144
Comparison of the Safety and Efficacy of Ustekinumab and Vedolizumab in Patients with Crohn’s Disease: A Systematic Review and Meta-Analysis of Propensity Score Matched Cohort Studies 143
An HCC Aggressiveness Index and Blood GTP, Bilirubin and Platelet Levels 143
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 143
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score 143
A significant proportion of patients with chronic hepatitis B who are candidates for antiviral treatment are untreated: a region-wide survey in Italy 142
Alpha-fetoprotein in hepatocellular carcinoma surveillance: wake not the dead. 142
Eltrombopag in patients with chronic liver disease. 142
Feasibility of the cut-and-push method for removing large caliber, soft, percutaneous endoscopic gastrostomy devices. 142
Significance of platelet and AFP levels and liver function parameters for HCC size and survival. 142
Totale 16.637
Salva come PNG Salva come JPEG
Categoria #
all - tutte 160.873
article - articoli 158.830
book - libri 0
conference - conferenze 316
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.727
Totale 321.746
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021276 0 0 0 0 0 0 0 0 0 0 0 276
2021/20224.035 174 266 310 354 126 252 239 997 267 360 209 481
2022/20233.705 384 228 37 284 603 614 34 361 685 21 391 63
2023/20241.986 95 277 40 238 171 229 128 120 116 74 153 345
2024/20256.539 232 483 229 382 868 666 586 1.091 262 288 629 823
2025/202613.039 1.253 430 1.147 1.204 1.455 1.290 1.937 599 980 1.536 950 258
Totale 47.608